Search results
Results From The WOW.Com Content Network
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG. [15] On April 9, 2019, Alcon completed a 100% spin-off from Novartis. [4] [16] [17] The new standalone company is worth up to 28 billion Swiss francs. [18]
FPJ's Ang Probinsyano is one of the Philippines' most-watched series. It currently holds the record for the highest-rated pilot episode of all time for any series since the Philippines switched to nationwide TV ratings system in 2009, at 41.6% in 2015, [ 166 ] as well as the second highest-rated telecast in the same period after the 2010 series ...
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
114 minutes. Country. Philippines. Language. Filipino. Ang Panday ( lit. 'The Blacksmith') is a 1980 Filipino action - fantasy film produced and directed by Fernando Poe Jr., who also stars as the titular character. It is based on the fictional comics character of the same name, created by Carlo J. Caparas and illustrated by Steve Gan.
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
February 13, 2023. ( 2023-02-13) –. present. ( present) FPJ's Batang Quiapo ( transl. FPJ's Quiapo kid) is a Philippine television drama action series broadcast by Kapamilya Channel. [ 2] Directed by Malu L. Sevilla, Darnel Joy R. Villaflor, Coco Martin and Kevin de Vela, it stars Martin in the title role. The series is based on the 1986 film ...
ZURICH/LONDON (Reuters) -Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday ...